معرفی
Alessandra Luchini serves as Professor in George Mason University's School of Systems Biology and the Center for Applied Proteomics and Molecular Medicine (CAPMM), where she pioneers nanotechnology solutions for cancer and infectious disease diagnostics. Her work bridges biomolecular interface engineering with clinical translation through advanced proteomic platforms.
Education
- Ph.D. from University of Padova, Italy
Research Focus: Dr. Luchini's program centers on nanoproteomics for biomarker discovery, specifically developing hydrogel-based affinity capture systems to detect urinary biomarkers of Lyme disease, Chagas disease, and tuberculosis. Her lab innovates in biomimetic membrane models using neutron reflectometry to study pathogen-host interactions, while translating findings into point-of-care diagnostic devices through CAPMM's clinical partnerships.
Publication Trends: Recent work (2024-2025) reveals three converging trajectories: (1) urinary peptide diagnostics for tick-borne illnesses validated against clinical symptom scores, (2) engineered nanoparticle networks for pathogen sequestration in blood/plasma, and (3) membrane biophysics studies enabling targeted drug delivery. This integration of basic membrane science with clinical proteomics defines her translational approach.
Awards
- 2023 SCHEV Outstanding Faculty Award for Virginia higher education
Research Leadership: As CAPMM principal investigator, Dr. Luchini directs NIH-funded projects developing FDA-cleared diagnostic platforms. Her team collaborates with CDC on Babesia diagnostics and with oncology centers on field cancerization proteomics, while mentoring postdocs in nanoparticle engineering and mass spectrometry techniques.
Infrastructure: The CAPMM core facility houses state-of-the-art mass spectrometers, neutron reflectometers, and GMP-compliant nanoparticle synthesis equipment, supporting her lab's work on urinary biomarker validation and affinity capture technology development.
